Literature DB >> 24277248

Soft Drugs VI. The Application of the Inactive Metabolite Approach for Design of Soft β-Blockers1?2.

N Bodor1, Y Oshiro, T Loftsson, M Katovich, W Caldwell.   

Abstract

The "inactive metabolite approach" was used to design β-blockers. The acidic inactive metabolite of metoprolol [4-(2-hydroxy-3-isopropylamino) propoxyphenylacetic acid] was used as the lead compound. Its esters (alkyl and cycloalkyl) were found active in vivo while reverting quantitatively to the same inactive metabolite in plasma. The cyclohexyl ester showed the best activity, which was cardioselective, similar to the parent compound metoprolol. Although most esters had a plasma half-life of approximately 1 min, their activity (antagonism of isoproterenol induced increase in heart rate) following intravenous administration lasted 45-90 minutes, and the maximum β-blockade was observed at 45-60 minutes in both rats and dogs.

Entities:  

Year:  1984        PMID: 24277248     DOI: 10.1023/A:1016376003515

Source DB:  PubMed          Journal:  Pharm Res        ISSN: 0724-8741            Impact factor:   4.200


  6 in total

1.  Metabolism of metoprolol-(3-h) in man, the dog and the rat.

Authors:  K O Borg; E Carlsson; K J Hoffmann; T E Jönsson; H Thorin; B Wallin
Journal:  Acta Pharmacol Toxicol (Copenh)       Date:  1975

2.  Combined pharmacokinetic and pharmacodynamic studies on alprenolol and 4-hydroxy-alprenolol in man.

Authors:  B Ablad; K O Borg; G Johnsson; C G Regårdh; L Sölvell
Journal:  Life Sci       Date:  1974-02-16       Impact factor: 5.037

3.  Determined of bufuralol and its metabolites in plasma by mass fragmentography and by gas chromatography with electron capture detection.

Authors:  R J Francis; P B East; S J McLaren; J Larman
Journal:  Biomed Mass Spectrom       Date:  1976-12

4.  Soft drugs V: Thiazolidine-type derivatives of progesterone and testosterone.

Authors:  N Bodor; K B Sloan
Journal:  J Pharm Sci       Date:  1982-05       Impact factor: 3.534

5.  The effect of impaired renal function on the plasma concentration and urinary excretion of metoprolol metabolites.

Authors:  K J Hoffmann; C G Regårdh; M Aurell; M Ervik; L Jordö
Journal:  Clin Pharmacokinet       Date:  1980 Mar-Apr       Impact factor: 6.447

6.  Plasma levels and beta-blocking effect of alpha-hydroxymetoprolol--metabolite of metoprolol--in the dog.

Authors:  C G Regårdh; L Ek; K J Hoffmann
Journal:  J Pharmacokinet Biopharm       Date:  1979-10
  6 in total
  4 in total

Review 1.  Ophthalmic drug design based on the metabolic activity of the eye: soft drugs and chemical delivery systems.

Authors:  Nicholas Bodor; Peter Buchwald
Journal:  AAPS J       Date:  2005-12-07       Impact factor: 4.009

2.  Soft drugs. XX. Design, synthesis, and evaluation of ultra-short acting beta-blockers.

Authors:  H S Yang; W M Wu; N Bodor
Journal:  Pharm Res       Date:  1995-03       Impact factor: 4.200

3.  Soft drugs. 19. Pharmacokinetics, metabolism and excretion of a novel soft corticosteroid, loteprednol etabonate, in rats.

Authors:  N Bodor; W M Wu; T Murakami; S Engel
Journal:  Pharm Res       Date:  1995-06       Impact factor: 4.200

4.  Metabolism, distribution, and transdermal permeation of a soft corticosteroid, loteprednol etabonate.

Authors:  N Bodor; T Loftsson; W M Wu
Journal:  Pharm Res       Date:  1992-10       Impact factor: 4.200

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.